No abstract available
Publication types
-
Case Reports
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Base Sequence
-
Carcinoma, Transitional Cell / drug therapy
-
Carcinoma, Transitional Cell / radiotherapy
-
Carcinoma, Transitional Cell / surgery
-
Chemotherapy, Adjuvant / adverse effects
-
Chromosome Breakage
-
Chromosomes, Human, Pair 11 / genetics*
-
Chromosomes, Human, Pair 11 / ultrastructure
-
Chromosomes, Human, Pair 14 / genetics*
-
Chromosomes, Human, Pair 14 / ultrastructure
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Combined Modality Therapy
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives
-
Fatal Outcome
-
Gemcitabine
-
Humans
-
Leukemia, Myeloid, Acute / genetics*
-
Male
-
Middle Aged
-
Molecular Sequence Data
-
Neoplasms, Radiation-Induced / genetics
-
Neoplasms, Second Primary / genetics*
-
Nephrectomy
-
Oncogene Proteins, Fusion / genetics*
-
Radiotherapy, Adjuvant / adverse effects
-
Urologic Neoplasms / drug therapy
-
Urologic Neoplasms / radiotherapy
-
Urologic Neoplasms / surgery
Substances
-
MLL-KIAA0284 fusion protein, human
-
Oncogene Proteins, Fusion
-
Cytarabine
-
Deoxycytidine
-
Cisplatin
-
Daunorubicin
-
Gemcitabine